BBG Advanced Therapies was recently highlighted in a GlobalData feature examining the emerging role of extracellular vesicles (EVs) in regenerative medicine and targeted drug delivery.
EVs are naturally occurring particles released by cells that carry biologically active cargo—including proteins, lipids, and nucleic acids—to neighboring cells. By delivering these molecular signals, EVs can influence cellular behavior, modulate immune responses, and support tissue repair.
Because EVs cannot replicate like living cells, they may offer several advantages compared with traditional cell therapies, including:
- Reduced risk of engraftment-related complications
- Greater immune compatibility
- Improved stability for storage and distribution
However, moving EV therapies from promising research to clinical reality requires robust, scalable manufacturing strategies. The GlobalData article highlights how BBG Advanced Therapies supports EV development through a tailored approach that includes:
- Donor screening and cell bank development
- Process development and optimization
- Scalable upstream and downstream manufacturing
- Advanced analytical testing and characterization
These capabilities help innovators maintain consistency, purity, and reproducibility as Extracellular vesicles programs advance toward clinical evaluation.
Download the expert insight article to learn more about how new biomanufacturing approaches are helping address some of the biggest challenges in advanced therapy development.
